<h1>Company cites positive three-year trial of physiology-guided complete revascularization with drug-eluting stent ahead of IPO filing</h1> A medical device company reported three-year, multicenter randomized trial results showing that physiology-guided complete revascularization using its drug-eluting stent in elderly myocardial infarction patients with multivessel disease reduced a composite endpoint (all-cause death, MI, stroke, revascularization) versus culprit-only treatment and demonstrated low stent thrombosis rates at 1 and 3 years. The company has filed a draft red herring prospectus with the national securities regulator for a proposed IPO, subject to regulatory approvals, market conditions and risks; the filing includes standard investor risk disclosures and a caution that the DRHP should not be solely relied upon for investment decisions.